Molecular oncogene markers and their significance in cutaneous malignant melanoma

Background: Oncogenes and other molecular tumor markers that predict tumor aggressiveness may allow individualization and optimization of surgical therapy of intermediate-thickness malignant melanoma. We examined the expression of selected markers, including the HLA-DR antigen, the heat shock protein-70 (HSP-70), and the c-myc oncogene in primary melanoma and regional nodes and related these findings to metastatic potential and survival. Methods: Forty patients with primary melanoma (1.5–4.0 mm) were studied, all of whom had prophylactic lymph node dissection and were followed for 18 months to 7 years. The primary tissue and nodes were examined using immunohistochemical techniques for the presence of HLA-DR antigen and HSP-70 protein and the expression of the c-myc oncogene. Results: Of 40 patients, there were 23 with lesions 1 to 2.9 mm thick and 17 with lesions 3 to 4 mm thick. Nodal metastases were present in 25 of the 40 patients who had elective node dissection. HLA-DR antibody stained the primary tumor in 10 patients (25%), but there was no correlation with survival in this group. HLA-DR antibody stained the stroma and cellular infiltrates surrounding the primary tumor in 28 of 40 patients; in this group there was a correlation of HLA-DR staining of the peritumoral stroma with improved survival overall. HLA-DR staining of the peritumoral stroma also influenced survival when patients were stratified by tumor thickness groups 1 to 2.9 mm and 3 to 4 mm and presence of nodal metastases. HSP-70 was demonstrated in the primary tumor in 25% of patients, who were also shown to have significantly improved survival when compared with those whose primary tumor did not stain with HSP-70. C-myc was expressed in the primary tumor in 25%, but showed no correlation with survival. None of these proteins correlated with or predicted the presence of nodal metastases. Conclusion: We conclude that the use of specific molecular-oncogene markers in intermediate-thickness primary melanoma may identify patients at high risk for conventional treatment failure and reduced survival who may profit from more aggressive surgery, adjuvant therapy, or both.Presented at the 48th Annual Cancer Symposium of The Society of Surgical Oncology, Boston, Massachusetts, March 23–26, 1995.     

参附注射液对大鼠缺血再灌注小肠细胞Bax、Bcl-2及c-myc蛋白表达的影响

目的　探讨参附注射液对大鼠缺血再灌注小肠细胞Bax、Bcl 2及c myc蛋白表达的影响及它们与肠细胞凋亡的内在联系。方法　健康SD大鼠 36只随机分为 3组 ,空白对照组 (S组 )、缺血再灌注 +生理盐水组 (IR +NS组 )、缺血再灌注 +参附注射液组 (IR +SF组 ) ,每组 12只。采用钳闭肠系膜前动脉制备小肠缺血再灌注模型。免疫组化检测Bax、Bcl 2及c myc蛋白的表达 ,每组选 2 4个视野分别测量光密度值 (OD值 )。TUNEL法检测凋亡的小肠细胞并计算凋亡指数。结果　IR +NS组BaxOD值明显高于S组 (P <0 .0 1) ,IR +SF组BaxOD值明显低于IR +NS组 (P <0 .0 1) ,且低于S组 (P <0 .0 5 )。IR +NS组Bcl 2OD值高于S组 (P <0 .0 5 ) ,且IR +SF组Bcl 2OD值高于S组 (P <0 .0 1) ,但IR +NS组与IR +SF组比较无显著差异。IR +NS组c mycOD值明显高于S组 (P<0 .0 1) ,且明显高于IR +SF组 (P <0 .0 1)。IR +NS组细胞凋亡指数明显高于S组和IR +SF组 (P <0 .0 1) ,而IR +SF组高于S组 (P <0 .0 5 )。结论　参附注射液增加小肠组织Bcl 2蛋白的表达 ,降低Bax及c myc蛋白的表达 ,抑制小肠细胞凋亡 ,保护缺血再灌注小肠。     

c-myc mRNA在成釉细胞瘤中的表达

目的:研究成釉细胞瘤(AB)和牙源性角化囊肿(OKC)中c-mycmRNA的表达,探讨c-myc在AB和OKC中的发生、发展及其生物学意义。方法:使用原位杂交法检测54例AB、16例OKC和7例口腔正常黏膜(NOM)组织中c-mycmRNA的表达,并将AB按原发、复发、恶变分组,结果使用χ2检验进行统计分析。结果:AB、OKC及NOM组织中c-mycmRNA的阳性表达率分别为81.5%(44/54)、75.0%(12/16)和14.3%(1/7),3组比较有显著性差异(χ2=15.488,P<0.05)。原发组AB中c-mycmRNA的阳性表达率为71.0%,复发组为94.7%,恶变组为100.0%,伴随原发、复发、恶变,差异有显著性(χ2=16.912,P﹤0.05)。结论:c-myc表达在AB的发生、发展中有重要作用;c-mycmRNA的表达与AB的临床生物学行为有关,伴随其生物学行为变化,c-mycmRNA表达增强;提示c-myc有可能成为评价预后的有效指标。     

Lack of Allelic Preference in Amplification and Loss of the c-myc Oncogene in Methylcholanthrene-induced Mouse Sarcomas

Sarcomas were induced in Fl mice between C57BL/6N and C3H/He strains by subcutaneous injection of methylcholanthrene. The c-myc oncogene was found to be amplified in 16 cases among 43 sarcomas of C57BL/6N × C3H/He mice and 1 case among 5 sarcomas of the reciprocal cross. The origin of the amplified allele was determined by the polymerase chain reaction single strand conformation polymorphism analysis. Among the 17 sarcomas, only one had both of the alleles amplified. The rest of the tumors carried the amplified c-myc allele coming either from C57BL/6N (9 cases) or from C3H/He (8 cases). These results indicate that the c-myc allele is amplified randomly in methylcholanthrene-induced mouse sarcomas irrespective of its origin, such as paternal or maternal allele and C57BL/6N or C3H/He allele. In addition to these changes, the unamplified c-myc oncogene was found to be lost in 12 cases out of the 17 sarcomas with the amplification.     

Partial restoration of B cell development in Jak-3(-/-) mice achieved by co-expression of IgH and E(mu)-myc transgenes

Jak-3 is a non-receptor tyrosine kinase that plays an important role in coordinating signals received through a wide range of cytokine receptors, including the IL-7 receptor (IL-7R). Jak-3-deficient mice have a profound block in B cell development at the pro-to-pre-B cell transition and have very few peripheral B cells. This block has been postulated to reflect the inability of Jak-3(-/-) pro-B cells to respond to IL-7. Here we demonstrate that B cell development can be partially restored in Jak-3-deficient mice when they are bred to mice carrying both a rearranged Ig heavy chain (IgH/Igmu) transgene and a c-myc transgene expressed in the B cell lineage. Jak-3(-/-) mice expressing both of these transgenes exhibit significant increases in the number of B cells in the bone marrow and, to a lesser extent, in the spleen. However, very few rescued B cells were detectable in mice greater than 4 months of age. To determine whether resident hyperactivated Jak-3(-/-) peripheral T cells are responsible for the elimination of the rescued B cells in older mice, we bred IgH transgenic (Igmu Tg)/myc Tg/Jak-3(-/-) mice to T cell-deficient (TCRalpha(-/-)) mice. Data from these experiments suggest that the paucity of B cells in older Jak-3(-/-) mice is largely attributable to the lack of Jak-3 in the B cells themselves. Thus, Jak-3 seems to play several important roles in B cells: during development, to enable cell division, Ig gene rearrangement and cell differentiation, and in mature cells, to promote B cell survival in the periphery.     

c-myc和p53蛋白在宫颈癌组织中的表达及临床意义

目的探讨c myc和p53蛋白在宫颈癌中表达的临床意义。方法采用免疫组化法检测51例正常宫颈、宫颈上皮内瘤样病变(CIN)和宫颈鳞癌中的c myc和p53蛋白的表达,并用TUNEL法检测细胞凋亡数。结果正常宫颈c myc和p53未见表达,宫颈鳞癌c myc和p53表达高于CIN(P<0.05)。宫颈鳞癌和CIN的TUNEL标记率均低于正常宫颈,宫颈鳞癌与CIN及正常组比较相差非常显著(P<0.01)。结论细胞凋亡可能与宫颈癌的形成过程有关,c myc和p53蛋白过度表达在宫颈癌的发生发展中起很重要的作用。     

P~(53)andc-myc蛋白在食管癌及癌前病变中的表达意义

目的　探讨P53 及c -myc蛋白在食管癌及癌前病变中的表达及意义。方法　应用免疫组化SP法检测P53 及c -myc在 6 0例食管癌及 33例非典型增生中的表达。 结果　P53 及c -myc蛋白分别在食管癌与非典型增生I～II级中表达有显著差异 (P <0 .0 5 ) ;在食管癌与非典型增生III级表达中无显著差异 (P >0 .0 5 )。结论　P53 及c -myc蛋白异常表达 ,可为食管癌和癌前病变界限的划分提供参考依据。     

大鼠胃黏膜癌变过程细胞凋亡及相关癌基因bcl—2、c—myc的动态表达

目的：探讨大鼠胃黏膜癌变发生发展过程中细胞凋亡及其相关基因的关系。方法：采用MNNG,10％NaCl及酒精灌胃建立了大鼠胃黏膜癌变模型,设立正常空白组,模型组,分别用TUNEL,原位杂交技术及免疫组化大鼠检测胃黏膜细胞凋亡指数,bcl-2,c-myc基因表达。结果：本造模方法成功率较高。从正常胃黏膜到胃癌,细胞凋亡指数逐渐下降,bcl-2,c-myc基因表达逐渐增高,大鼠胃黏膜细胞凋亡受到抑制与bcl-2,c-myc基因高表达具有高度的一致性,结论：细胞凋亡失控是胃黏膜癌变发生发展的机制之一,bcl-2,c-myc基因可能参与了对大鼠胃黏膜癌变细胞凋亡的调控。     

The role of c-myc in regulating mdr1 gene expression in tumor cell line KB

Ｔｈｅｃ ｍｙｃｐｒｏｔｏ ｏｎｃｏｇｅｎｅｐｌａｙｓａｒｏｌｅｉｎｍａｎｙｃｅｌｌｕｌａｒｐｒｏｃｅｓｓｅｓ ,ｓｕｃｈａｓｐｒｏｌｉｆｅｒａｔｉｏｎ ,ｄｉｆｆｅｒｅｎｔｉａｔｉｏｎａｎｄａｐｏｐｔｏｓｉｓ Ｉｔｉｓａｎｅａｒｌｙ ｒｅｓｐｏｎｓｅｇｅｎｅｎｅｃｅｓｓａｒｙｆｏｒｃｅｌｌ ｃｙｃｌｅｐｒｏｇｒｅｓｓｉｏｎ (Ｇ1 Ｓｔｒａｎｓｉｔｉｏｎ)ａｎｄａｃｔｉｖａｔｅｓｑｕｉｅｓｃｅｎｔｃｅｌｌｓｉｎｔｏｔｈｅｃｅｌｌｃｙｃｌｅ (Ｇ0 Ｇ1ｔｒａｎｓｉｔｉｏｎ) Ｄｏｗｎ ｒｅｇｕｌａｔｉｏｎｏｆｃ …